DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Status of the Claims
Applicant’s submission filed 17 August 2026 has been entered. Claims 1-28, 30-34, and 37-42 are pending. Claims 24 and 34 have been amended. Therefore, prosecution on the merits continues for claims 24-28, 30-34, and 37-42 as being drawn to the elected invention, with claims 1-23 withdrawn for reading on the non-elected invention(s). All arguments have been fully considered with the status of each prior ground of rejection set forth below.
Status of Prior Rejections/Response to Arguments
RE: Objection to claim 34
Applicant’s amendment to instant claim 34 correcting the minor informality obviates the objection of record.
Therefore, the objection is withdrawn.
RE: Rejection of claims 24-28, 30-34, and 37-42 under 35 USC 112(a) – written description
Applicant's arguments filed 17 August 2026 have been fully considered but they are not persuasive.
Applicant has traversed the rejection, asserting in Pages 10-12 of the Remarks filed 17 August 2026 that the provided examples within the disclosure address the technical problem of developing an alternative non-viral delivery method that is efficient yet gentle on cells, as Examples 4-5 of the disclosure demonstrate that the SOLUPORE™ delivery method has minimal impact on protein and gene expression in T cells, and that biological attributes such as proliferation and gene expression profiles are preserved. More specifically, Applicant asserts that Example 4 of the disclosure demonstrates that unactivated T cells transfected using the SOLUPORE™ delivery method exhibit no change in gene expression when compared to untreated controls. With that, Applicant asserts that Example 5 of the disclosure demonstrates that the SOLUPORE™ delivery method can efficiently deliver cargo to modify T cells such that the modified T cells retain their desired biological attributes such as proliferation and in vivo engraftment. Applicant then concludes that it would have been reasonable for a skilled artisan to predict that the addition of cargo to the delivery solution would not have changed the minimal stress experienced by the cells subjected to the SOLUPORE™ delivery method, unless the cargo itself causes such an effect. In response, the Examiner respectfully submits that Example 4 of the disclosure mock-transfects the unactivated T cells – such that there is no alcohol nor exogenous cargo within the isotonic delivery solution – to avoid any confounding effects the exogenous cargo may have on gene expression. See, for example, Paragraphs [0209]-[0220] and [0243] of the published disclosure. With that, the activation status of the T cells in Example 5 is unknown, as it is not explicitly disclosed, and thus cannot be relied upon to teach that the addition of exogenous cargo and ethanol in the isotonic delivery solution does not significantly impact the gene expression of unactivated T cells given the unpredictability in the art between responses of unactivated and activated T cells. See, for example, Paragraphs [0221]-[0224] of the published disclosure, Pages 10-12 of the Remarks filed 26 June 2025, and Pages 12-13 of the Remarks filed 09 January 2026. Accordingly, the ordinary artisan cannot look to the examples provided within the disclosure to reasonably predict that the treatment of unactivated T cells with an isotonic delivery solution comprising ethanol and an exogenous cargo will have no impact on the gene expression of the unactivated T cells, specifically the T-cell exhaustion related genes. It is also of note that the provision of an exogenous cargo within the isotonic delivery solution is required in independent claims 24 and 34, as is the unchanged gene expression of the T-cell exhaustion related genes. Accordingly, the effects of the exogenous cargo on the SOLUPORE™ delivery method must be accounted for.
Therefore, the rejection is maintained and amended to encompass the claims as currently written.
RE: Rejection of claims 24-28, 30-34, and 37-42 under 35 USC 112(a) – scope of enablement
Applicant's arguments filed 17 August 2026 have been fully considered but they are not persuasive.
Applicant has traversed the rejection, asserting in Page 13 of the Remarks filed 17 August 2026 that the amendments to each of independent claims 24 and 34 limiting the non-adherent immune cell to a T cell, the alcohol to ethanol with a concentration up to 30% (v/v), and the T cells to having an immune function when compared to a population of the same T cells that have not experienced a cell engineering step overcome the rejection of record, as the disclosure provides various examples of treating T cells with the isotonic aqueous solution as presently claimed. In response, the Examiner respectfully submits that the disclosure provides one example (Example 4) wherein unactivated T cells are treated with an isotonic aqueous solution however, since the unactivated T cells are mock-transfected, there is no exogenous cargo or ethanol present in the isotonic aqueous solution. See, for example, Paragraph [0243] of the published disclosure, which states the ethanol is only added to the isotonic solution for the delivery of mRNA and RNPs. Accordingly, given the unpredictability in the art between the treatment of unactivated versus activated T cells, the ordinary artisan would not have been able to reasonably perform the claimed invention with the examples provided by the disclosure.
Therefore, the rejection is maintained and amended to encompass the claims as currently written.
RE: Rejection of claims 24-28, 30-34, and 37-42 under 35 USC 112(b)
Applicant’s amendments to each of independent claims 24 and 34 clarifying the reference population of non-adherent immune cells that has not experienced an engineering step obviate the rejections of record.
Therefore, the rejections are withdrawn.
New/Maintained Grounds of Rejection
Claim Objections
Claim 34 is objected to because of the following informalities:
Regarding claim 34: The instant claim is objected to for failing to provide a conjunctive word between the final “wherein” limitation of method step (b) and method step (c).
Appropriate correction is required.
Claim Rejections - 35 USC § 112
The following is a quotation of the first paragraph of 35 U.S.C. 112(a):
(a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention.
The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112:
The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention.
Claims 24-28, 30-34, and 37-42 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claims contain subject matter which was not described in the Specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention.
Independent claim 24 is directed to a method of engineering a non-adherent immune cell, the method comprising,
(a) providing a population of non-adherent immune cells; and
(b) contacting the population of non-adherent immune cells with a volume of an isotonic aqueous solution, the aqueous solution comprising an exogenous cargo and up to about 30% (v/v) alcohol, the alcohol being ethanol, wherein the population of non-adherent immune cells is unactivated during (a) and (b),
wherein an immune function of the population of non-adherent immune cells from steps (a) and (b) is that of a population of the non-adherent immune cells that has not experienced a cell engineering step,
wherein the immune cell function comprises gene expression of T-cell exhaustion related genes comprising FBJ murine osteosarcoma viral oncogene homolog B (FOSB), v-Fos FBJ Murine Osteosarcoma Viral Oncogene (FOS), v-jun avian sarcoma virus 17 oncogene (JUN), Basic leucine zipper transcription factor ATF-like (BATF), Basic leucine zipper transcriptional factor ATF-like 3 (BATF3), or Interferon regulatory factor 4 (IRF4), and
wherein the non-adherent immune cell is a T cell.
With that, independent claim 34 is directed to a method of delivering at least two exogenous cargos across the plasma membrane of a non-adherent immune cell, comprising
(a) providing a population of non-adherent immune cells,
(b) using at least two intracellular delivery methods comprising:
(i) an intracellular delivery method comprising contacting the population of cells with a volume of an isotonic aqueous solution, the aqueous solution comprising the exogenous cargo and up to about 30% (v/v) alcohol, the alcohol being ethanol, wherein the population of non-adherent immune cells is unactivated, and
(ii) an intracellular delivery method selected from (1) contacting the population of cells with a volume of an isotonic aqueous solution, the aqueous solution comprising the exogenous cargo and up to about 30% (v/v) alcohol, the alcohol being ethanol, (2) viral transduction, (3) electroporation, or (4) nucleofection,
wherein an immune function of the population of non-adherent immune cells from steps (a) and (b) is that of a population of the non-adherent immune cells that has not experienced a cell engineering step,
wherein the immune cell function comprises gene expression of T-cell exhaustion related genes comprising FBJ murine osteosarcoma viral oncogene homolog B (FOSB), v-Fos FBJ Murine Osteosarcoma Viral Oncogene (FOS), v-jun avian sarcoma virus 17 oncogene (JUN), Basic leucine zipper transcription factor ATF-like (BATF), Basic leucine zipper transcriptional factor ATF-like 3 (BATF3), or Interferon regulatory factor 4 (IRF4), and
wherein the non-adherent immune cell is a T cell;
(c) thereby delivering the two exogenous cargos to the non-adherent immune cell.
Thus, to satisfy the written description aspect of 35 U.S.C. 112(a) for a claimed group – or genus – of isotonic aqueous solutions, MPEP §2163 recites, “[t]he written description requirement for a claimed genus may be satisfied through sufficient description of a representative number of species by actual reduction to practice, reduction to drawings, or by disclosure of relevant, identifying characteristics, i.e., structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure, or by a combination of such identifying characteristics, sufficient to show the applicant was in possession of the claimed genus…when there is substantial variation within the genus, one must describe a sufficient variety of species to reflect the variation within the genus. For inventions in an unpredictable art, adequate written description of a genus which embraces widely variant species cannot be achieved by disclosing only one species within the genus.”
The written description inquiry is limited to that which is contained within the four corners of the Specification, not the extent to which the skilled artisan, given his or her knowledge of the art, would have considered it to expand with only routine experimentation. See Ariad Pharms. Inc. v. Eli Lilly & Co., 598 F.3d 1336, 1351 (Fed. Cir. 2010); see also id. at 1352 (“[I]t is the specification itself that must demonstrate possession. . . . a description that merely renders the invention obvious does not satisfy the requirement.").
Regarding disclosure of identifying characteristics of the claimed groups, a review of the Specification fails to provide a definition of the structural characteristics the species encompassed by the current claims must have. As such, Applicant has failed to identify any particular core chemical structure or function (along with a correlation between function and a specific conserved structure) of the isotonic aqueous solutions; and thus one of ordinary skill in the art would not immediately envisage all possible species of the groups as currently claimed. Therefore, Applicant has not disclosed the identifying characteristics of the claimed groups.
More specifically, in giving the term ‘isotonic aqueous solution’ its broadest reasonable interpretation, the number and types of solutions which can be considered a species of an isotonic aqueous solution is extraordinarily great, as they can include any isotonic aqueous solution comprising ethanol at any concentration up to 30% and any exogenous cargo. Applicant’s disclosure does not provide any definitions for the respective groups, instead broadly stating within Paragraphs [0046] and [0060]-[0061] of the published Specification detail that the aqueous solution is “isotonic with respect to the cytoplasm of a mammalian cell such as a human T cell” and can preferably comprise 25 percent (v/v) of an alcohol, while Paragraphs [0025] and [0058]-[0060] of the published Specification broadly state that the “exogenous cargo” is a cargo (or payload) coming from or deriving from outside the cell, and can include a small chemical molecule, a peptide or protein, nucleic acid, therapeutic agent, or alcohol.
The courts have described the essential question to be addressed in a description requirement issue in a variety of ways. An objective standard for determining compliance with the written description requirement is, "does the description clearly allow persons of ordinary skill in the art to recognize that he or she invented what is claimed." In re Gosteli, 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989). Under Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), to satisfy the written description requirement, an applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention, and that the invention, in that context, is whatever is now claimed. The test for sufficiency of support in a parent application is whether the disclosure of the application relied upon "reasonably conveys to the artisan that the inventor had possession at that time of the later claimed subject matter." Ralston Purina Co. v. Far-Mar-Co., Inc., 772 F.2d 1570, 1575, 227 USPQ 177, 179 (Fed. Cir. 1985) (quoting In re Kaslow, 707 F.2d 1366, 1375, 217 USPQ 1089, 1096 (Fed. Cir. 1983)). Whenever the issue arises, the fundamental factual inquiry is whether the specification conveys with reasonable clarity to those skilled in the art that, as of the filing date sought, applicant was in possession of the invention as now claimed. See, e.g., Vas-Cath, Inc. v. Mahurkar, 935 F.2d 1555, 1563-64, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991). See M.P.E.P. § 2163.02. In this case, the skilled artisan would not have reasonably concluded at the time of the invention that applicant was in possession of the entire invention as claimed.
Applicant’s disclosure also fails to provide a sufficient number of exemplary isotonic aqueous solutions given the breadth of each respective genus. More specifically, Applicant has provided a single working example of treating unactivated non-adherent T cells with a single isotonic aqueous solution. However, it is of note that the unactivated non-adherent T cells within this working example were mock-transfected such that the isotonic aqueous solution did not comprise an exogenous cargo or concentration of alcohol, which does not read on the methods of the instant claims. See Example 4 and Paragraphs [0242]-[0243] of the published disclosure.
The written description requirement is in place to ensure that “when a patent claims a genus by its function or result, the specification recites sufficient materials to accomplish that function.” Ariad Pharms. Co. v. Eli Lilly & Co., 94 U.S.P.Q.2d 1161, 1172 (Fed. Cir. 2010) (en banc). A consideration of the four corners of the Specification does not reflect that Applicant has actually invented the scope of the claimed invention, since the working examples are primarily limited to the treatment of activated T cells or PBMCs with a single isotonic aqueous solution comprising a concentration of ethanol and examination of a relatively minute number of exogenous cargos. With that, the lone working example utilizing unactivated non-adherent T cells that have been treated with a single isotonic aqueous solution – which does not comprise an alcohol or exogenous cargo – is not sufficient to fulfill the written description requirement for a sufficient description of a representative number of species, which is required to claim the entire genus of an unactivated non-adherent immune cell that has been treated with “an isotonic aqueous solution comprising an exogenous cargo and up to about 30% (v/v) ethanol”, as required by the instant claims. Additionally, there is no disclosure of relevant, identifying characteristics, such as structure or other physical or chemical properties, or functional characteristics sufficient to show that Applicant was in possession of the claimed genera. See Eli Lilly, 119F. 3d. at 1568, 43 USPQ2d at 1406, and MPEP § 2163. Therefore, the Specification does not permit the skilled artisan to visualize all of the members of the genus being administered in the claimed methods.
If claims merely recite a “description of the problem to be solved while claiming all solutions to it” and “cover any compound later actually invented and determined to fall within the claim’s functional boundaries,” they have not met the description requirement. Ariad, 94 U.S.P.Q.2d at 1172.
Furthermore, the Examiner notes that the prior art in regard to the claims is unpredictable. More specifically, there are inherent structural and functional differences between unactivated and activated immune cells. Berard et al disclose that unactivated – or naïve – T cells have a lower expression of adhesion and migratory molecules when compared to activated T cells, which affect their ability to migrate to non-lymphoid tissues and respond to antigens – or their immune function. See Pages 127, 129-130 of Berard et al (Immunology, 2002, of record). With that, O’Dea et al disclose that aqueous solutions comprising greater than 30% - which includes “about 30%” – ethanol rapidly permeabilize the plasma membrane and are toxic to the treated immune cells. See Pages 2-3 and 7 of O’Dea et al (PLOS ONE, 2017, of record). It is also of note that the published Specification suggests that extrapolating data from the working examples to a generic teaching is not predictable, as the comparison of gene expression in the cells differed when represented by log 2 fold change or linear fold change. See Paragraphs [0081]-[0084] and Figure 12 of the published Specification.
Accordingly, Applicant’s disclosure appears to be an investigation of a mechanism wherein treatment of unactivated non-adherent T cells with an isotonic solution comprising ethanol and an exogenous cargo does not alter the immune function of the unactivated non-adherent T cells. However, [p]atents are not awarded for academic theories, no matter how groundbreaking or necessary to the later patentable inventions of others.” Ariad, 94 U.S.P.Q.2d at 1173. The patent system is designed to give incentives to complete inventions, not to guess at the future. Id. at 1174.
Taken together, the lack of disclosure of species, lack of an established structure-function relationship in the Specification or prior art, and unpredictability of the prior art, a skilled artisan would not conclude that Applicant was in possession of the claimed invention. Accordingly, the claims are considered to lack sufficient written description and are properly rejected under 35 USC 112(a). Claims 25-28, 30-33, and 37-42 are included because they depend from a rejected claim and also lack sufficient written description.
Claims 24-28, 30-34, and 37-42 remain rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, because the Specification, while being enabling for the treatment of activated T cells with an isotonic aqueous solution comprising ethanol and an exogenous cargo, and having an unaltered immune function when compared to an untranslated control, does not reasonably provide enablement for the treatment of unactivated non-adherent T cells with any isotonic aqueous solution comprising any exogenous cargo and up to 30% (v/v) ethanol, and having an unaltered immune function when compared to a population of the non-adherent T cells that has not experienced a cell engineering step. The instant Specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims, as the instant claims are directed to a method of engineering a non-adherent T cell (emphasis added).
Possession of an invention may be shown in a variety of ways including description of an actual reduction to practice, or by showing that the invention was "ready for patenting" such as by the disclosure of drawings or structural chemical formulas that show that the invention was complete, or by describing distinguishing identifying characteristics sufficient to show that the applicant was in possession of the claimed invention. See, e.g., Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 68, 119 S.Ct. 304, 312, 48 USPQ2d 1641, 1647 (1998). Although working examples are not required, the claimed invention is required to be enabled so that any person skilled in the art can make and use the invention without undue experimentation. See MPEP § 2164.
The factors to be considered in determining whether a disclosure would require undue experimentation include:
A) The breadth of the claims;
(B) The nature of the invention;
(C) The state of the prior art;
(D) The level of one of ordinary skill;
(E) The level of predictability in the art;
(F) The amount of direction provided by the inventor;
(G) The existence of working examples; and
(H) The quantity of experimentation needed to make or use the invention based on the content of the disclosure.
In re Wands, 8 USPQ2d, 1400 (CAFC 1988) and MPEP § 2164.01.
Nature of the invention: Independent claim 24 is directed to a method of engineering a non-adherent immune cell, the method comprising,
(a) providing a population of non-adherent immune cells; and
(b) contacting the population of non-adherent immune cells with a volume of an isotonic aqueous solution, the aqueous solution comprising an exogenous cargo and up to about 30% (v/v) alcohol, the alcohol being ethanol, wherein the population of non-adherent immune cells is unactivated during (a) and (b),
wherein an immune function of the population of non-adherent immune cells from steps (a) and (b) is that of a population of the non-adherent immune cells that has not experienced a cell engineering step,
wherein the immune cell function comprises gene expression of T-cell exhaustion related genes comprising FBJ murine osteosarcoma viral oncogene homolog B (FOSB), v-Fos FBJ Murine Osteosarcoma Viral Oncogene (FOS), v-jun avian sarcoma virus 17 oncogene (JUN), Basic leucine zipper transcription factor ATF-like (BATF), Basic leucine zipper transcriptional factor ATF-like 3 (BATF3), or Interferon regulatory factor 4 (IRF4), and
wherein the non-adherent immune cell is a T cell.
With that, independent claim 34 is directed to a method of delivering at least two exogenous cargos across the plasma membrane of a non-adherent immune cell, comprising
(a) providing a population of non-adherent immune cells,
(b) using at least two intracellular delivery methods comprising:
(i) an intracellular delivery method comprising contacting the population of cells with a volume of an isotonic aqueous solution, the aqueous solution comprising the exogenous cargo and up to about 30% (v/v) alcohol, the alcohol being ethanol, wherein the population of non-adherent immune cells is unactivated, and
(ii) an intracellular delivery method selected from (1) contacting the population of cells with a volume of an isotonic aqueous solution, the aqueous solution comprising the exogenous cargo and up to about 30% (v/v) alcohol, the alcohol being ethanol, (2) viral transduction, (3) electroporation, or (4) nucleofection,
wherein an immune function of the population of non-adherent immune cells from steps (a) and (b) is that of a population of the non-adherent immune cells that has not experienced a cell engineering step,
wherein the immune cell function comprises gene expression of T-cell exhaustion related genes comprising FBJ murine osteosarcoma viral oncogene homolog B (FOSB), v-Fos FBJ Murine Osteosarcoma Viral Oncogene (FOS), v-jun avian sarcoma virus 17 oncogene (JUN), Basic leucine zipper transcription factor ATF-like (BATF), Basic leucine zipper transcriptional factor ATF-like 3 (BATF3), or Interferon regulatory factor 4 (IRF4), and
wherein the non-adherent immune cell is a T cell;
(c) thereby delivering the two exogenous cargos to the non-adherent immune cell.
The relative skill of those in the art: The relative skill of those in the art is high, with the majority of ordinary artisans possessing an advanced degree.
The breadth of the claims: With respect to claim breadth, the standard under 35 U.S.C. §112(a) entails the determination of what the claims recite and what the claims mean as a whole. In addition, when analyzing for enablement, the claims are analyzed with respect to the teachings of the Specification and are to be “given their broadest reasonable interpretation consistent with the Specification.” See MPEP § 2111 [R-5]; Phillips v. AWH Corp., 415 F.3d 1303, 75 USPQ2d 1321 (Fed. Cir. 2005); and In re Hyatt, 211 F.3d 1367, 1372, 54 USPQ2d 1664, 1667 (Fed. Cir. 2000). Applicant always has the opportunity to amend the claims during prosecution, and broad interpretation by the Examiner reduces the possibility that the claim, once issued, will be interpreted more broadly than is justified. In re Prater, 415 F.2d 1393, 1404-05, 162 USPQ 541, 550- 51 (CCPA 1969).
As such, the broadest reasonable interpretation of the instantly claimed methods includes any isotonic aqueous solution comprising any type of exogenous cargo and ethanol at any concentration up to about 30 percent. A skilled artisan would not know how to engineer a non-adherent T cell with a reasonable expectation of success based solely on what is disclosed in the Specification.
The amount of direction or guidance presented: The instant Specification fails to exemplify the engineering of an unactivated non-adherent T cell, wherein the unactivated non-adherent T cell is contacted with an isotonic aqueous solution comprising a concentration of ethanol up to 30% (v/v) and an exogenous cargo. Instead, the closest working example contacts unactivated non-adherent T cells with an isotonic aqueous solution that does not comprise alcohol or an exogenous cargo. See Example 4, which correlates to Paragraphs [0209]-[0220] of the published Specification. This fails to provide specific details necessary to successfully perform the full scope of the claimed method.
The presence or absence of working examples: As aforementioned, the instant Specification only provides working examples either for the engineering of activated non-adherent T cells with an isotonic aqueous solution comprising a concentration of ethanol and exogenous cargo, or for the mock-transfection of unactivated non-adherent T cells using an isotonic aqueous solution that does not comprise alcohol or an exogenous cargo. See Example 4, which correlates to Paragraphs [0209]-[0220] of the published Specification. Therefore, Applicant has not provided sufficient evidence of the engineering of an unactivated non-adherent T cell using any isotonic aqueous solution comprising ethanol and any exogenous cargo.
The level of predictability in the art and quantity of experimentation necessary: The standard of an enabling disclosure is not the ability to make and test if the invention works but one of the ability to make and use with a reasonable expectation of success. A patent is granted for a completed invention, not the general suggestion of an idea and how that idea might be developed into the claimed invention.
The prior art appears to be silent with regard to demonstrating the engineering of unactivated non-adherent immune cells with an isotonic aqueous solution comprising an alcohol and exogenous cargo. More specifically, the disclosure of O’Dea et al (PLOS ONE, 2017, of record) utilizes a hypotonic aqueous solution comprising 25% ethanol and an exogenous fluorescent protein cargo on unactivated non-adherent T cells, while the disclosure of Maguire et al (WO 2018/115973 A2, of record) engineers activated non-adherent immune cells using an isotonic aqueous solution comprising 27% ethanol and an exogenous fluorescent protein cargo. Given that the use of unactivated versus activated immune cells is unpredictable – which Applicant has persuasively argued in Pages 10-12 of the Remarks filed 26 June 2025 and Pages 12-13 of the Remarks filed 09 January 2026, and is suggested in Pages 127, 129-130 of Berard et al (Immunology, 2002) – the full scope of the claim term “isotonic aqueous solution… comprising an exogenous cargo and up to about 30% (v/v) ethanol” is thus not enabled in regards the engineering of a non-adherent immune cell, since at best it would require undue trial and error experimentation.
Claims 25-28, 30-33, and 37-42 are included because they depend from a rejected claim and do not enable the recited claim language. See MPEP § 2164.08.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to ALYSSA G WESTON whose telephone number is (571)272-0337. The examiner can normally be reached Monday-Thursday 8AM - 4PM (CT); Friday 8AM - 11AM (CT).
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Christopher Babic can be reached at (571) 272-8507. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/ALYSSA G WESTON/Examiner, Art Unit 1633
/CHRISTOPHER M BABIC/Supervisory Patent Examiner, Art Unit 1633